modelCrospovidone
Extends from Pharmacolibrary.Drugs.ATC.A.A07BC03.
Information
| name: | Crospovidone | |
| ATC code: | A07BC03 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
Crospovidone is a cross-linked form of polyvinylpyrrolidone (PVP) used as a tablet disintegrant in pharmaceutical formulations. It is an inert, insoluble polymer that rapidly absorbs water and swells, promoting tablet breakup and aiding in drug release. Crospovidone is not an active drug but a pharmaceutical excipient, and is not used for therapeutic treatment. It is generally recognized as safe and is approved for use in many countries.
Pharmacokinetics
No relevant pharmacokinetic publications are available for crospovidone in humans, as it is not absorbed or pharmacologically active. The compound is considered pharmacologically inert, non-bioavailable, and serves only as a disintegrant in solid oral dosage forms.
References
Alsalhi, A, et al., & Batchelor, HK (2025). Flexible and dispersible paediatric oral formulations produced via extrusion spheronisation for the treatment of tuberculosis. International journal of pharmaceutics 678 125701–None. DOI:10.1016/j.ijpharm.2025.125701 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40350000
Mittapalli, RK, et al., & Yamsani, MR (2010). Varying efficacy of superdisintegrants in orally disintegrating tablets among different manufacturers. Die Pharmazie 65(11) 805–810. PUBMED:https://pubmed.ncbi.nlm.nih.gov/21155386
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)